Consequently, despite the 1639 TFs encoded in the human genome,[30] only a small fraction has been linked to PRAD and NEPC, leaving many critical regulators unidentified.[31] This gap, compounded by the predominant focus on a handful well‐characterized TFs, underscores the need for a more comprehensive approach to fully delineate the TF landscape in PCa, capturing both established and novel regulators implicated in tumor evolution and therapy resistance. Here, TF is linked to posterior cortical atrophy.